(Source: Cambridge Cognition Holdings plc) CANTAB Mobile awarded FDA clearance Posted on 25 January 2017 Cambridge Cognition today announces it has received 510(k) clearance from the U.S. Food and Drug Administration ('FDA') to market CANTAB Mobile as a medical device in the U.S. CANTAB Mobile is designed to detect clinically-relevant memory impairment in older adults at the point of care. It includes a computerised test of visuospatial associative learning (CANTAB PAL) to assess episodic memory with optional mood and functional...